-
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib
Zwierenga, F., Muntinghe-Wagenaar, M. B., Rozendal, P., de Langen, A. J., Hendriks, L. E. L., van den Heuvel, M., van der Leest, C., Hashemi, S. M. S., van der Leest, P., Hiltermann, T. J. N., Schuuring, E. & van der Wekken, A. J., Jul 2025, In: Targeted oncology. 20, 4, p. 663-677 15 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib
Riess, J. W., de Langen, A. J., Ponce, S., Goldberg, S. B., Piotrowska, Z., Goldman, J. W., le, X., Cho, B. C., Yoneshima, Y., Ambrose, H., Cavazzina, R., Tang, K. H., Lau, J. & Yu, H. A., 1 Jun 2025, In: JCO Precision Oncology. 9, e2400818.Research output: Contribution to journal › Article* › Academic › peer-review
-
Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET-Guided Verification
van der Gaag, S., Jordens, T., Yaqub, M., Grijseels, R., van Valkengoed, D. W., de Langen, E. N., van den Broek, R., Thijssen, V. L. J. L., de Langen, A. J., Kouwenhoven, M. C. M., Bahce, I., Westerman, B. A., Hendrikse, N. H. & Bartelink, I. H., May 2025, In: CPT: Pharmacometrics and Systems Pharmacology. 14, 5, p. 918-928 11 p.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
